<DOC>
	<DOC>NCT02260154</DOC>
	<brief_summary>Prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg BID and changes in quality of life in patients with post-cholecystectomy gastro-intestinal spasms</brief_summary>
	<brief_title>Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm</brief_title>
	<detailed_description />
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Muscle Cramp</mesh_term>
	<mesh_term>Postcholecystectomy Syndrome</mesh_term>
	<mesh_term>Mebeverine</mesh_term>
	<mesh_term>Alverine</mesh_term>
	<criteria>Male or female ≥ 18 years to 65 years; Patients suffering from postcholecystectomy GIspasms in the last 3 months with symptom onset at least 6 months prior to inclusion and not requiring surgical treatment; Laparoscopic cholecystectomy between 6 months to 5 years before enrollment; Patients having been prescribed Duspatalin® (mebeverine) 200 mg BID (bis in die = twice a day) in accordance with approved local label; Patient's written authorization to provide data for the program General and specific contraindications to Duspatalin® treatment according to the local label; Planned Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or surgical treatment; Being currently treated or having been treated with Duspatalin® within the 6 weeks prior to entering the program; Pregnancy or lactation; Other conditions that make patient participation impossible (by investigator judgment); Previous enrollment in the present program; Treatment with other antispasmodics, painmedication (Nonsteroidal antiinflammatory drugs (NSAIDs), tramadol, etc.) within 2 weeks prior to inclusion into the observational study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Duspatalin</keyword>
	<keyword>mebeverine</keyword>
	<keyword>cholecystectomy</keyword>
	<keyword>gastrointestinal spasm</keyword>
	<keyword>abdominal pain</keyword>
	<keyword>dyspepsia</keyword>
	<keyword>antispasmodics</keyword>
</DOC>